Elevation Oncology Statistics
Share Statistics
Elevation Oncology has 59.12M shares outstanding. The number of shares has increased by 21.52% in one year.
| Shares Outstanding | 59.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.02M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 6.15M, so 10.41% of the outstanding shares have been sold short.
| Short Interest | 6.15M |
| Short % of Shares Out | 10.41% |
| Short % of Float | 11.83% |
| Short Ratio (days to cover) | 8.55 |
Valuation Ratios
The PE ratio is -0.4 and the forward PE ratio is -0.76.
| PE Ratio | -0.4 |
| Forward PE | -0.76 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.33 |
| P/FCF Ratio | -0.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Elevation Oncology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.22, with a Debt / Equity ratio of 0.55.
| Current Ratio | 21.22 |
| Quick Ratio | 21.22 |
| Debt / Equity | 0.55 |
| Total Debt / Capitalization | 35.48 |
| Cash Flow / Debt | -1.86 |
| Interest Coverage | -10.9 |
Financial Efficiency
Return on equity (ROE) is -0.83% and return on capital (ROIC) is -53.53%.
| Return on Equity (ROE) | -0.83% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -53.53% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.58M |
| Employee Count | 29 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 30.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -69.53% in the last 52 weeks. The beta is 1.25, so Elevation Oncology 's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -69.53% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 1.9 |
| Relative Strength Index (RSI) | 59.77 |
| Average Volume (20 Days) | 1.71M |
Income Statement
| Revenue | n/a |
| Gross Profit | -39.00K |
| Operating Income | -45.45M |
| Net Income | -45.70M |
| EBITDA | -41.47M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.34 |
Balance Sheet
The company has 49.26M in cash and 30.14M in debt, giving a net cash position of 19.12M.
| Cash & Cash Equivalents | 49.26M |
| Total Debt | 30.14M |
| Net Cash | 19.12M |
| Retained Earnings | -195.97M |
| Total Assets | 106.30M |
| Working Capital | 99.40M |
Cash Flow
In the last 12 months, operating cash flow was -56.18M and capital expenditures 0, giving a free cash flow of -56.18M.
| Operating Cash Flow | -56.18M |
| Capital Expenditures | 0 |
| Free Cash Flow | -56.18M |
| FCF Per Share | -1.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELEV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -171.79% |
| FCF Yield | -121.15% |
Analyst Forecast
The average price target for ELEV is $7, which is 797.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 797.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -2.4 |
| Piotroski F-Score | 3 |